# Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
Canonical URL: https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-top-line-data-from-phase-2b-study-of-oral-omadacycline-omc-in-nontuberculous-mycobacterial-ntm-abscessus-pulmonary-disease
Ticker: PRTK
Company: Paratek Pharmaceuticals
Source: Paratek Pharmaceuticals
Published: 2024-11-08 09:00 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul type="circle"><li>First randomized placebo-controlled trial in NTM <em>abscessus</em></li><li>Symptom-based endpoints showed favorable improvement in frequency and severity of the most c

## Article Body
First randomized placebo-controlled trial in NTM abscessus

Symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms

Microbiologic endpoints showed higher conversion to negative sputum culture, without emergence of resistance to omadacycline

In this 12-week study,...
## Recent Company News
- 2026-04-16 07:30 EST — [Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-escmid-global-2026) — Source: Paratek Pharmaceuticals
- 2026-03-18 07:00 EST — [Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-combination-with-radius-health-expanding-its-multi-product-specialty-commercial-platform) — Source: Paratek Pharmaceuticals
- 2026-02-24 07:30 EST — [Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-results-for-nuzyrar-therapeutic-efficacy-studies-in-inhalation-anthrax-triggering-additional-procurement-under-barda-project-bioshield-contract) — Source: Paratek Pharmaceuticals
- 2025-10-17 07:30 EST — [Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-idweek-2025-and-chest-2025) — Source: Paratek Pharmaceuticals
- 2025-05-21 08:26 EST — [Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-of-specialty-therapies) — Source: Paratek Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)